サマリー

中東とアフリカのG-CSF/PEG-G-CSF市場は、2023年から2030年にかけて4.1%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
中東アフリカのG-CSF/PEG-G-CSF市場、適応症別（好中球減少症、腫瘍、慢性・自己免疫疾患、血液疾患、成長調和不全、その他）、投与量（単剤、配合剤）、投与経路（静脈内、皮下）、包装（単剤バイアル、プレフィルドシリンジ)、エンドユーザー（病院・クリニック、研究・学術機関、外来手術センター、その他）、流通チャネル（病院薬局、オンライン薬局、小売薬局、その他）、国（南アフリカ、サウジアラビア、エジプト、イスラエル、UAE、クウェート、オマーン、中東・アフリカのその他）の産業動向と2030年までの予測

中東・アフリカのG-CSF/PEG-G-CSF市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 血液がんやがん疾患の増加
- 発熱性好中球減少症の増加例
市場のプレイヤー：

中東・アフリカのG-CSF/PEG-G-CSF市場で活動している主要な市場関係者は以下の通りです：
- ルパン
- ビオシダス
- USVプライベート・リミテッド
- ヴィアトリス社
- バイオコン
- フレゼニウス・カビAG
- アムジェン社
- ファイザー株式会社
- サンド・インターナショナル社
- ドクター・レディーズ・ラボラトリーズ・リミテッド（Dr. Reddy's Laboratories Ltd.
- アコードヘルスケア
- ナップ・ファーマシューティカルズ・リミテッド
- インタス・ファーマシューティカルズ・リミテッド
- ムンディファーマ・インターナショナル
- テバ・ファーマシューティカル・インダストリーズ社
- 協和キリン株式会社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 24
1.4 LIMITATIONS 26
1.5 MARKETS COVERED 26
2 MARKET SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 CURRENCY AND PRICING 31
2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
2.6 MULTIVARIATE MODELLING 35
2.7 TYPE LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 MARKET END USER COVERAGE GRID 38
2.11 VENDOR SHARE ANALYSIS 39
2.12 SECONDARY SOURCES 40
2.13 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 44
4.1 PESTEL ANALYSIS 45
4.2 PORTER’S FIVE FORCES 46
4.3 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 47
4.4 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 48
4.5 STRATEGIES TO THE ENTER THE MARKET 48
4.5.1 JOINT VENTURE (PARTNERSHIPS): 48
4.5.2 ACQUISITION: 48
4.5.3 LINE EXPANSION VIA COLLABORATION: 48
4.5.4 PRODUCT APPROVAL: 49
4.5.5 PRODUCT LAUNCH: 49
4.5.6 GEOGRAPHIC EXPANSION: 49
4.5.7 COST LEADERSHIP: 50
4.5.8 PRODUCT DEVELOPMENT: 50
4.6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 51
4.6.1 PATENT ANALYSIS 51
4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 52
4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
4.6.4 THERAPEUTIC ASSESSMENT 52
4.6.5 KEY PRICING STRATEGIES 53
4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 53
4.6.7 CONCLUSION 53
4.7 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 54
5 EPIDEMIOLOGY 55
6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET: REGULATIONS 58
7 MARKET OVERVIEW 61
7.1 DRIVERS 63
7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 63
7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 64
7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 65
7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 66
7.2 RESTRAIN 67
7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 67
7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 68
7.3 OPPORTUNITIES 69
7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 69
7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 69
7.4 CHALLENGES 70
7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 70
7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 70
8 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION 71
8.1 OVERVIEW 72
8.2 NEUTROPENIA 76
8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 77
8.2.2 SEVERE CHRONIC NEUTROPENIA 77
8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 77
8.2.4 NEUTROPENIA IN HIV PATIENTS 77
8.2.5 CLOZAPINE INDUCED NEUTROPENIA 77
8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 77
8.2.7 CONGENITAL NEUTROPENIA 77
8.3 ONCOLOGY 78
8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 78
8.3.2 OTHERS 79
8.4 CHRONIC AND AUTO IMMUNE DISEASES 79
8.5 BLOOD DISORDERS 79
8.6 GROWTH HORMONE DEFICIENCY 80
8.7 OTHERS 81
9 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 82
9.1 OVERVIEW 83
9.2 MONO 86
9.3 COMBINATION 87
10 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 88
10.1 OVERVIEW 89
10.2 SUBCUTANEOUS 92
10.3 INTRAVENOUS 93
11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 94
11.1 OVERVIEW 95
11.2 PRE FILLED SYRINGES 98
11.3 SINGLE USE VIALS 99
12 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER 100
12.1 OVERVIEW 101
12.2 HOSPITALS AND CLINICS 104
12.3 RESEARCH & ACADEMIC INSTITUTES 104
12.4 AMBULATORY SURGICAL CENTERS 105
12.5 OTHERS 106
13 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 107
13.1 OVERVIEW 108
13.2 HOSPITALS PHARMACY 111
13.3 RETAIL PHARMACY 111
13.4 ONLINE PHARMACY 112
13.5 OTHERS 113
14 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET, BY REGION 114
14.1 MIDDLE EAST AND AFRICA 115
14.1.1 SOUTH AFRICA 121
14.1.2 SAUDI ARABIA 129
14.1.3 EGYPT 136
14.1.4 ISRAEL 144
14.1.5 UAE 151
14.1.6 KUWAIT 157
14.1.7 OMAN 164
15 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 171
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 171
16 SWOT ANALYSIS 172
17 COMPANY PROFILE 173
17.1 PFIZER INC. 173
17.1.1 COMPANY SNAPSHOT 173
17.1.2 REVENUE ANALYSIS 174
17.1.3 COMPANY SHARE ANALYSIS 174
17.1.4 PRODUCT PORTFOLIO 175
17.1.5 RECENT DEVELOPMENTS 175
17.2 VIATRIS INC. 176
17.2.1 COMPANY SNAPSHOT 176
17.2.2 REVENUE ANALYSIS 176
17.2.3 COMPANY SHARE ANALYSIS 177
17.2.4 PRODUCT PORTFOLIO 177
17.2.5 RECENT DEVELOPMENT 177
17.3 AMGEN INC. 178
17.3.1 COMPANY SNAPSHOT 178
17.3.2 REVENUE ANALYSIS 178
17.3.3 COMPANY SHARE ANALYSIS 179
17.3.4 PRODUCT PORTFOLIO 179
17.3.5 RECENT DEVELOPMENTS 179
17.4 STADA ARZENEIMITTEL AG 181
17.4.1 COMPANY SNAPSHOT 181
17.4.2 COMPANY SHARE ANALYSIS 181
17.4.3 PRODUCT PORTFOLIO 182
17.4.4 RECENT DEVELOPMENT 182
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 183
17.5.1 COMPANY SNAPSHOT 183
17.5.2 REVENUE ANALYSIS 183
17.5.3 COMPANY SHARE ANALYSIS 184
17.5.4 PRODUCT PORTFOLIO 184
17.5.5 RECENT DEVELOPMENTS 184
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 185
17.6.1 COMPANY SNAPSHOT 185
17.6.2 PRODUCT PORTFOLIO 185
17.6.3 RECENT DEVELOPMENTS 185
17.7 ACCORD HEALTHCARE 186
17.7.1 COMPANY SNAPSHOT 186
17.7.2 PRODUCT PORTFOLIO 186
17.7.3 RECENT DEVELOPMENTS 186
17.8 AMNEAL PHARMACEUTICALS LLC. 187
17.8.1 COMPANY SNAPSHOT 187
17.8.2 REVENUE ANALYSIS 187
17.8.3 PRODUCT PORTFOLIO 188
17.8.4 RECENT DEVELOPMENTS 188
17.9 APOTEX INC. 189
17.9.1 COMPANY SNAPSHOT 189
17.9.2 PRODUCT PORTFOLIO 189
17.9.3 RECENT DEVELOPMENT 189
17.10 BIOCON 190
17.10.1 COMPANY SNAPSHOT 190
17.10.2 REVENUE ANALYSIS 190
17.10.3 PRODUCT PORTFOLIO 191
17.10.4 RECENT DEVELOPMENT 191
17.11 BIO SIDUS 192
17.11.1 COMPANY SNAPSHOT 192
17.11.2 PRODUCT PORTFOLIO 192
17.11.3 RECENT DEVELOPMENTS 192
17.12 CADILA PHARMACEUTICALS 193
17.12.1 COMPANY SNAPSHOT 193
17.12.2 PRODUCT PORTFOLIO 193
17.12.3 RECENT DEVELOPMENTS 193
17.13 COHERUS BIOSCIENCES 194
17.13.1 COMPANY SNAPSHOT 194
17.13.2 REVENUE ANALYSIS 194
17.13.3 PRODUCT PORTFOLIO 195
17.13.4 RECENT DEVELOPMENT 195
17.14 DR. REDDY’S LABORATORIES LTD 196
17.14.1 COMPANY SNAPSHOT 196
17.14.2 REVENUE ANALYSIS 196
17.14.3 PRODUCT PORTFOLIO 197
17.14.4 RECENT DEVELOPMENTS 197
17.15 FRESENIUS KABI AG 198
17.15.1 COMPANY SNAPSHOT 198
17.15.2 PRODUCT PORTFOLIO 198
17.15.3 RECENT DEVELOPMENT 198
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 199
17.16.1 COMPANY SNAPSHOT 199
17.16.2 PRODUCT PORTFOLIO 199
17.16.3 RECENT DEVELOPMENTS 199
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 200
17.17.1 COMPANY SNAPSHOT 200
17.17.2 PRODUCT PORTFOLIO 200
17.17.3 RECENT DEVELOPMENTS 200
17.18 INTAS PHARMACEUTICALS LTD. 201
17.18.1 COMPANY SNAPSHOT 201
17.18.2 PRODUCT PORTFOLIO 201
17.18.3 RECENT DEVELOPMENT 201
17.19 KASHIV BIOSCIENCES, LLC. 202
17.19.1 COMPANY SNAPSHOT 202
17.19.2 PRODUCT PORTFOLIO 202
17.19.3 RECENT DEVELOPMENT 202
17.20 KYOWA KIRIN CO., LTD. 203
17.20.1 COMPANY SNAPSHOT 203
17.20.2 REVENUE ANALYSIS 203
17.20.3 PRODUCT PORTFOLIO 204
17.20.4 RECENT DEVELOPMENT 204
17.21 LUPIN 205
17.21.1 COMPANY SNAPSHOT 205
17.21.2 REVENUE ANALYSIS 205
17.21.3 PRODUCT PORTFOLIO 206
17.21.4 RECENT DEVELOPMENT 206
17.22 MUNDIPHARMA INTERNATIONAL. 207
17.22.1 COMPANY SNAPSHOT 207
17.22.2 PRODUCT PORTFOLIO 207
17.22.3 RECENT DEVELOPMENT 207
17.23 NAPP PHARMACEUTICALS LIMITED 208
17.23.1 COMPANY SNAPSHOT 208
17.23.2 PRODUCT PORTFOLIO 208
17.23.3 RECENT DEVELOPMENT 208
17.24 RELIANCE LIFE SCIENCES 209
17.24.1 COMPANY SNAPSHOT 209
17.24.2 PRODUCT PORTFOLIO 209
17.24.3 RECENT DEVELOPMENTS 209
17.25 SANDOZ INTERNATIONAL GMBH 210
17.25.1 COMPANY SNAPSHOT 210
17.25.2 REVENUE ANALYSIS 210
17.25.3 PRODUCT PORTFOLIO 211
17.25.4 RECENT DEVELOPMENTS 211
17.26 SPECTRUM PHARMACEUTICALS, INC. 212
17.26.1 COMPANY SNAPSHOT 212
17.26.2 PRODUCT PORTFOLIO 212
17.26.3 RECENT DEVELOPMENT 212
17.27 USV PRIVATE LIMITED 213
17.27.1 COMPANY SNAPSHOT 213
17.27.2 PRODUCT PORTFOLIO 213
17.27.3 RECENT DEVELOPMENTS 213
18 QUESTIONNAIRE 214
19 RELATED REPORTS 217

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 58
TABLE 2 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 75
TABLE 3 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 76
TABLE 4 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 76
TABLE 5 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 6 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 78
TABLE 7 MIDDLE EAST & AFRICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 8 MIDDLE EAST & AFRICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 9 MIDDLE EAST & AFRICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 10 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 85
TABLE 12 MIDDLE EAST & AFRICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 13 MIDDLE EAST & AFRICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 14 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 91
TABLE 15 MIDDLE EAST & AFRICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 92
TABLE 16 MIDDLE EAST & AFRICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 17 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 97
TABLE 18 MIDDLE EAST & AFRICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 98
TABLE 19 MIDDLE EAST & AFRICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 20 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 103
TABLE 21 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 104
TABLE 22 MIDDLE EAST & AFRICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105
TABLE 23 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 105
TABLE 24 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 25 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 110
TABLE 26 MIDDLE EAST & AFRICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 111
TABLE 27 MIDDLE EAST & AFRICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 112
TABLE 28 MIDDLE EAST & AFRICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 112
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113
TABLE 30 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118
TABLE 31 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118
TABLE 32 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 118
TABLE 33 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 118
TABLE 34 MIDDLE EAST AND AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119
TABLE 35 MIDDLE EAST AND AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119
TABLE 36 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 119
TABLE 37 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 120
TABLE 38 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 120
TABLE 39 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 120
TABLE 40 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 120
TABLE 41 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121
TABLE 42 SOUTH AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121
TABLE 43 SOUTH AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122
TABLE 44 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 122
TABLE 45 SOUTH AFRICA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 122
TABLE 46 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 122
TABLE 47 SOUTH AFRICA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123
TABLE 48 SOUTH AFRICA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123
TABLE 49 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 123
TABLE 50 SOUTH AFRICA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123
TABLE 51 SOUTH AFRICA SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
TABLE 52 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 124
TABLE 53 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
TABLE 54 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 124
TABLE 55 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125
TABLE 56 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
TABLE 57 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 125
TABLE 58 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125
TABLE 59 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
TABLE 60 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
TABLE 61 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 126
TABLE 62 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 126
TABLE 63 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 64 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
TABLE 65 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
TABLE 66 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 67 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 127
TABLE 68 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
TABLE 69 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 70 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
TABLE 71 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
TABLE 72 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129
TABLE 73 SAUDI ARABIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129
TABLE 74 SAUDI ARABIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130
TABLE 75 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 130
TABLE 76 SAUDI ARABIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130
TABLE 77 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 130
TABLE 78 SAUDI ARABIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131
TABLE 79 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 131
TABLE 80 SAUDI ARABIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131
TABLE 81 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 131
TABLE 82 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
TABLE 83 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132
TABLE 84 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 132
TABLE 85 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
TABLE 86 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132
TABLE 87 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133
TABLE 88 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 89 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
TABLE 90 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133
TABLE 91 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 133
TABLE 92 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
TABLE 93 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134
TABLE 94 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
TABLE 95 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
TABLE 96 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134
TABLE 97 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
TABLE 98 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
TABLE 99 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135
TABLE 100 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 135
TABLE 101 EGYPT G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136
TABLE 102 EGYPT NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136
TABLE 103 EGYPT ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137
TABLE 104 EGYPT G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 137
TABLE 105 EGYPT MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 137
TABLE 106 EGYPT G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 137
TABLE 107 EGYPT SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138
TABLE 108 EGYPT G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 138
TABLE 109 EGYPT PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138
TABLE 110 EGYPT G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 138
TABLE 111 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
TABLE 112 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 139
TABLE 113 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 139
TABLE 114 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
TABLE 115 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140
TABLE 116 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140
TABLE 117 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
TABLE 118 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140
TABLE 119 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140
TABLE 120 EGYPT G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 141
TABLE 121 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 141
TABLE 122 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
TABLE 123 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141
TABLE 124 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142
TABLE 125 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 142
TABLE 126 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 142
TABLE 127 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142
TABLE 128 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 143
TABLE 129 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143
TABLE 130 ISRAEL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144
TABLE 131 ISRAEL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144
TABLE 132 ISRAEL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145
TABLE 133 ISRAEL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 145
TABLE 134 ISRAEL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 145
TABLE 135 ISRAEL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 145
TABLE 136 ISRAEL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
TABLE 137 ISRAEL INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
TABLE 138 ISRAEL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 146
TABLE 139 ISRAEL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146
TABLE 140 ISRAEL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 147
TABLE 141 ISRAEL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147